Roles of Achieved Levels of Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein on Cardiovascular Outcome in Statin Therapy

Figure 1

The cumulative incidences of total MACE, according to achieved LDL-C level and followed-up hsCRP level before and after adjustment of potential confounding factors. ^†Major adverse cardiovascular event, was a composite of total death, acute myocardial infarction and cardiac death, de novo percutaneous coronary intervention, atrial fibrillation (AF), heart failure, and stroke. ^‡Potential compounding factors are the following; age, sex, cardiovascular risk factors (HTN, DM, CKD, HF, AF, and angina pectoris), co-medications (aspirin, clopidogrel, cilostazol, warfarin, BB, diuretics, ARB, ACEI, CCB, nitrates, trimetazidine, nicorandil, and molsidomine). Quartile 2 and Quartile 3 were slightly overlapped. MACE; major adverse cardiovascular events; LDL-C, low-density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; HR, hazard ratio; CI, confidential intervals; N/A, not available; HTN, hypertension; DM, diabetes mellitus; CKD, chronic kidney disease; HF, heart failure; AF, atrial fibrillation; BB, beta blocker; ARB, angiotensin II receptor blocker; ACEi, angiotensin converting enzyme inhibitor; CCB, calcium channel.

(a)

(b)

(c)

(d)